NEW YORK (GenomeWeb) – NanoString Technologies today announced that the European Society for Medical Oncology has added the PAM50 gene signature to its clinical practice guidelines as a prognostic and predictive tool to determine benefit from chemotherapy.

NanoString's Prosigna Breast Cancer Gene Signature Assay is based on the PAM50 gene signature and runs on the firm's nCounter Dx Analysis System. The guidelines acknowledge the test has achieved an evidence level of 1B for its prognostic value, meaning its value has been demonstrated in individual randomized controlled trials.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.